| Drug Name |
Asparaginase |
| Drug ID |
BADD_D00175 |
| Description |
Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels of non-essential amino acid, asparagine, in lymphoblastic leukemic cells thus promoting apoptotic cell death [A31999]. For patients who develop hypersensitivity to _E. coli_-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated [DB08886] is recommended [A31999]. |
| Indications and Usage |
Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) [FDA Label]. |
| Marketing Status |
Prescription |
| ATC Code |
L01XX02 |
| DrugBank ID |
DB00023
|
| KEGG ID |
D02997
|
| MeSH ID |
D001215
|
| PubChem ID |
5460875
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
81561-413 |
| Synonyms |
Asparaginase | Asparagine Deaminase | Deaminase, Asparagine | Colaspase | Asparaginase II | Erwinase | Paronal | Crasnitin | Kidrolase | Leunase | Elspar | Asparaginase medac | medac, Asparaginase |
